david ettinger, md, provides practical advice related to pd-l1 testing in metastatic nsclc patients
Published 8 years ago • 60 plays • Length 1:11
Download video MP4
Download video MP3
Similar videos
-
0:47
david ettinger, md, talks about levels of pd-l1 expression and agent selection
-
0:25
david ettinger, md, on choosing between immunotherapy and chemotherapy in metastatic nsclc patients
-
0:35
david ettinger, md, talks about impact of immunotherapy in 1st line metastatic nsclc patients
-
0:35
david ettinger, md, on cost of therapy when choosing agents for late stage lung cancer patients
-
0:56
david ettinger, md, on the positioning of ramucirumab (cyramza) for nsclc
-
0:54
david andorsky, md, provides examples of how rwe has impacted the oncology community
-
0:46
clinical trials in lung cancer explained video
-
1:17
is molecular imaging the best way to determine response to treatment?
-
0:49
nevena damjanov, md, considers the shortcomings of recist in measuring efficacy in hcc patients
-
10:46
session 4 discussion/questions/review (moderator: amish dave, md)
-
9:47
advocacy in action: who should have molecular testing when diagnosed with lung cancer?
-
0:31
david gandara, md, discusses pembrolizumab vs docetaxel for previously treated nsclc patients
-
2:32
david a. braun, md, phd, regarding the follow-up trial investigating mk-6482 in ccrcc
-
7:11
how to kill a trial
-
1:00
7 things to know about immunotherapy
-
1:37
early detection is key
-
5:33
prof richard boyd explores cancer immunotherapy
-
3:27
what other procedures does an interventional cardiologist perform?
-
1:16
david j. palmer, md
Clip.africa.com - Privacy-policy